ArticlePeptides2017
Angiotensin-(1-7)-dependent vasorelaxation of the renal artery exhibits unique angiotensin and bradykinin receptor selectivity.
Article in Peptides, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 34 citations in OpenAlex.
- Pharmacological Effects of Angiotensin 1-7 on Venous Vascular Tone.Biomedicines · 2026Article
- The potential role of thymoquinone in preventing the cardiovascular complications of COVID-19.Vascular pharmacology · 2021Review
- Angiotensin-(1-7)-A Potential Remedy for AKI: Insights Derived from the COVID-19 Pandemic.Journal of clinical medicine · 2021Review
- Fetal Growth Restriction and Hypertension in the Offspring: Mechanistic Links and Therapeutic Directions.The Journal of pediatrics · 2020Review
- ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.Hypertension (Dallas, Tex. : 1979) · 2020Review
- Analysis of complement deposition and viral RNA in placentas of COVID-19 patients.Annals of diagnostic pathology · 2020Article
- Fetal programming and the angiotensin-(1-7) axis: a review of the experimental and clinical data.Clinical science (London, England : 1979) · 2019Review
- Effects of Angiotensin-(1-7) and Angiotensin II on Acetylcholine-Induced Vascular Relaxation in Spontaneously Hypertensive Rats.Oxidative medicine and cellular longevity · 2019Article
- Angiotensin 1-7, but not the thrombin-cleaved osteopontin C-terminal fragment, attenuates osteopontin-mediated macrophage-induced endothelial-cell inflammation.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2018Article
- Angiotensin-(1-7) and the Regulation of Anti-Fibrotic Signaling Pathways.Journal of cell signaling · 2017Article
- Therapeutic Approaches to the Alternative Angiotensin-(1-7) Axis of the Renin-Angiotensin System.Annals of pharmacology and pharmaceutics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Angiotensin-(1-7) [Ang-(1-7)] exhibits blood pressure lowering actions, inhibits cell growth, and reduces tissue inflammation and fibrosis which may functionally antagonize an activated Ang II-AT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.